Recent developments highlight clinical progress, intellectual property expansion, and ongoing product development milestones.

• In January 2026, Autonomix presented compelling proof-of-concept clinical data showing rapid and durable pain relief across all disease stages of pancreatic cancer at the 2026 ASCO Gastrointestinal Cancers Symposium, demonstrating clinical progress in its lead indication [N1].
• The company announced successful completion of its initial trial phase and plans for a market expansion study in pancreatic cancer pain management, reflecting advancement in clinical development [N6].
• Autonomix reported successful Phase 1 trial results for pain management in pancreatic cancer and initiated a Phase 2 study, marking a key clinical milestone [N7].
• The company is actively enrolling patients in follow-on clinical trials to expand treatment options for cancer pain management, broadening its clinical scope [N5].
• Autonomix Medical strengthened its patent portfolio with issuance of U.S. Patent No. 12,295,646 for a smart torquer device in nerve-sensing technology, enhancing its intellectual property position [N2].
• The company expanded its global intellectual property portfolio with issuance of a U.S. patent for innovative nerve-targeted treatment technologies, supporting its platform's competitive moat [N3].
• Maxim Group initiated coverage of Autonomix Medical with a buy recommendation, indicating analyst interest and recognition of the company's potential [N8].
• Autonomix Medical announced plans to present innovative neural ablation technology at EuroPCR 2025, highlighting ongoing product development and industry engagement [N5].
• The company achieved design lock for its Apex 6 radiofrequency generator and advanced towards U.S. clinical trials for pancreatic cancer pain treatment, marking a significant product development milestone [N5].

Autonomix Medical's technology platform offers a novel approach to managing intractable pain and other nerve-related disorders through precise neural sensing and targeted radiofrequency ablation. The company's successful initial human proof-of-concept studies and ongoing expanded clinical trials demonstrate progress toward validating the platform's safety and efficacy. The issuance of multiple patents in key markets supports a strong intellectual property position, potentially enabling market exclusivity. The platform's minimally invasive catheter-based design could address significant unmet medical needs in oncology pain management and cardiovascular neuromodulation. Experienced management with a track record in medical device development and commercialization adds to execution capability. If clinical trials continue to show positive outcomes and regulatory approvals are obtained, the company could establish a differentiated position in a growing market for nerve-targeted therapies.

Autonomix Medical remains a development-stage company with no product revenue and significant operating losses. The transition from prototype to commercial-grade device involves technical and manufacturing challenges. Clinical trials are ongoing, and there is no guarantee of favorable outcomes or regulatory approvals. The company faces substantial capital requirements, with estimates of $30 to $36 million needed to fund operations through commercialization, creating dilution and financing risks. The company's Nasdaq listing is at risk due to share price below $1.00, with potential delisting impacting liquidity and investor confidence. Competition from established medical device companies and alternative pain management therapies could limit market adoption. Execution risks include scaling manufacturing, regulatory hurdles, and market acceptance of a novel technology platform.

Autonomix Medical's moat is based on its proprietary technology platform that combines advanced neural sensing with therapeutic radiofrequency ablation in a catheter-based device. The platform's key innovations include a proprietary antenna array capable of detecting extremely low-amplitude neural signals and an embedded microchip for local signal processing, enabling high-fidelity, real-time nerve signal detection and precise targeting. The company has secured multiple patents in the U.S. and Europe covering its nerve-sensing and ablation technologies, strengthening its intellectual property position. The integration of diagnostic and therapeutic functions in a minimally invasive catheter system addresses a significant unmet medical need in pain management and other nerve-related disorders. The company's early clinical proof-of-concept studies and ongoing trials provide initial validation of the technology's safety and feasibility. However, the company remains in the development stage, and the moat depends on successful commercialization, regulatory approvals, and competitive differentiation in a complex medical device market.

• Capital Requirements and Financing Risk: The company requires significant additional capital to fund ongoing clinical trials, product development, and commercialization efforts. Failure to secure adequate financing could force scaling back operations or delay development.
• Nasdaq Listing Compliance Risk: The company's common stock has traded below the $1.00 minimum bid price required for continued Nasdaq listing, with a compliance deadline in July 2026. Failure to regain compliance could result in delisting, adversely affecting liquidity and investor confidence.
• Clinical and Regulatory Risk: The technology is investigational and in early clinical stages. There is no assurance that clinical trials will demonstrate safety and efficacy or that regulatory approvals will be obtained.
• Manufacturing and Commercialization Risk: Scaling from prototype to commercial-grade device involves technical and manufacturing challenges. Delays or failures in this process could impact commercialization timelines.
• Market and Competitive Risk: The company faces competition from existing and emerging therapies for pain management and nerve disorders. Market acceptance of a novel technology platform is uncertain.

• Autonomix Medical, Inc. is a development-stage medical device company pioneering a first-in-class technology platform designed to sense and treat disorders of the nervous system.
• The lead system in development is a catheter-based solution combining diagnostic sensing and therapeutic radiofrequency (RF) ablation.
• The initial clinical focus is on intractable pain associated with pancreatic cancer, with plans to expand to other visceral cancers and nerve-related disorders including chronic pain, hypertension, and cardiovascular disease.
• The technology features a proprietary antenna array engineered to capture extremely low-amplitude neural signals and a proprietary microchip embedded within the catheter for local signal processing, enabling high-fidelity, real-time neural signal detection and interpretation.
• The product development strategy integrates diagnostic sensing to identify pathological nerve signals and therapeutic RF ablation to treat targeted nerves.
• Preclinical animal models demonstrated the ability to detect nerve signals before ablation and confirm signal termination after ablation.
• The company completed its initial first-in-human proof-of-concept study (PoC 1) in Q2 2025 evaluating safety and feasibility of transvascular RF ablation for pancreatic cancer pain.
• A follow-on study (PoC 2) has been initiated to expand treatment options to additional visceral cancers and earlier-stage pancreatic cancer patients.
• The company is refining catheter design to meet regulatory and manufacturing standards for human use and is working on scaling from prototype to commercial-grade device.
• Recent patents issued include U.S. Patent No. 12,369,852 and European Patent No. EP4230133 covering precision nerve-targeted therapies in cardiology, supporting catheter-based neuromodulation for hypertension, arrhythmia, heart failure, and refractory angina.
• The company has a strong intellectual property portfolio with multiple patents issued for nerve-sensing and ablation technologies.
• Management team includes CEO Brad Hauser (appointed June 2024), Chief Medical Officer Dr. Robert Schwartz (co-founder), Chief Technology Officer Landy Toth (founder), CFO Trent Smith (joined July 2023), and Executive Chairman Walter V. Klemp (joined January 2022).
• The company reported zero revenue for fiscal year ended March 31, 2026, with a net loss of $16.7 million and basic EPS of -$2.32 per share.
• As of March 31, 2026, cash and cash equivalents were $7.0 million, current assets $7.58 million, current liabilities $1.7 million, resulting in a current ratio of 4.45 and cash ratio of 4.11.
• The company is in the development stage and has not yet commercialized any products; clinical trials and product development are ongoing.
• Operating expenses increased notably in recent periods, driven by clinical trial and product development costs as well as stock-based compensation and legal fees.
• The company has disclosed risks including the need to raise additional capital estimated between $30 million to $36 million to fund operations through commercialization, and risks related to Nasdaq listing compliance due to share price below $1.00.
• The company received a Nasdaq deficiency letter in January 2026 for bid price below $1.00 and has a compliance period until July 13, 2026 to regain compliance or face potential delisting.
• The company completed a private placement in late 2025 raising approximately $2.5 million net proceeds through warrant inducements and common stock issuance.
• Recent clinical data presented at the 2026 ASCO Gastrointestinal Cancers Symposium showed rapid and durable pain relief across all disease stages of pancreatic cancer in proof-of-concept studies.
• The company continues to enroll patients in follow-on clinical trials expanding indications for cancer pain management.
• Maxim Group initiated coverage with a buy recommendation in April 2025, reflecting analyst interest in the company’s technology and clinical progress.